$LLY

Eli Lilly launched an online platform to dispense and deliver tirzepatide, a weight loss drug, after failing to get it listed on the PBS. The platform, already in the US and UK, will offer home delivery via a third-party pharmacy. Fiji declared a national emergency over its HIV crisis, and Australia's TGA removed Andrographis from approved medicine ingredients due to adverse reactions.

Eli Lilly's weekly insulin, Onswik, received FDA approval, offering patients over 300 fewer injections annually. The drug showed a 1.34% reduction in A1C levels in trials, compared to 1.26% for Novo's Tresiba. Lilly plans to launch Onswik in the U.S. soon, intensifying competition with Novo, which recently got approval for its own weekly insulin, Awiqli.

Eli Lilly (LLY) received FDA approval for Onswik, a once-weekly insulin for type 2 diabetes. The company's stock is deemed 26.0% undervalued with a GF Value of $1,554.72 vs. current price $1,150.99. LLY has a GF Score of 96/100, reflecting strong financial health and growth. Insider selling activity is noted, but institutional investors show confidence.

Eli Lilly received FDA approval for Onswik, a once-weekly basal insulin for type 2 diabetes. The company plans to make it available in the U.S. in two concentrations (500 and 1,000 units/mL) in the coming months.

InnoCare Pharma Ltd. announced a strategic research and licensing deal with Eli Lilly, potentially worth $3.35 billion. InnoCare will use its drug discovery platform to develop compounds against up to five targets. The company could receive up to $100 million in upfront payments and $3.25 billion in milestones, plus royalties. InnoCare focuses on cancer and autoimmune treatments, with three approved drugs and over 10 in development.

Apple led The Irish Times' Top 1,000 rankings with €209.3bn revenue and €72bn profit. Microsoft, Meta, and Google followed. Eli Lilly entered the top 10. CRH was the largest indigenous company. Apple and Meta reduced Irish headcounts. Irish corporation taxes surged due to tech profits.

InnoCare and Eli Lilly have agreed to a collaboration deal valued at up to $3.35 billion. The partnership focuses on developing and commercializing InnoCare's drug candidates in global markets, according to the companies.

Novo Nordisk (NVO) is seeking a U.S. court injunction to block Eli Lilly's (LLY) ads for Zepbound and Mounjaro, alleging misleading claims. Lilly denies wrongdoing. Analysts expect LLY to lead the GLP-1 market, with Mounjaro and Zepbound driving sales. NVO is down 8% YTD, while LLY is up 9.8%.

Viking Therapeutics (VKTX) shares rose after Phase 2 trial results showed its obesity drug VK2735 achieved 16%-19% weight reduction. The drug demonstrated progressive weight loss and maintained results during a 12-week maintenance phase. Morgan Stanley projects the global obesity drug market could reach $150B by 2035. Viking plans Phase 3 trials with results expected in late 2027 for injectable and 2028 for oral formulations. Analysts have a consensus price target of $90.89 for VKTX.

Eli Lilly's CEO reported that 700,000 American seniors have started GLP-1 weight-loss drugs since Medicare coverage began, with 70% using Lilly's medicines. The Medicare GLP-1 Bridge program covers the cost, with taxpayers paying $195 per patient monthly. Lilly's Zepbound injection and Foundayo pill are leading in sales, with Foundayo capturing 33% of new oral GLP-1 patients.